IBDEI256 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,34208,1,3,0)
 ;;=3^Neuroleptic-Induced Parkinsonism
 ;;^UTILITY(U,$J,358.3,34208,1,4,0)
 ;;=4^G21.11
 ;;^UTILITY(U,$J,358.3,34208,2)
 ;;=^5003772
 ;;^UTILITY(U,$J,358.3,34209,0)
 ;;=G24.01^^134^1731^15
 ;;^UTILITY(U,$J,358.3,34209,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34209,1,3,0)
 ;;=3^Tardive Dyskinesia
 ;;^UTILITY(U,$J,358.3,34209,1,4,0)
 ;;=4^G24.01
 ;;^UTILITY(U,$J,358.3,34209,2)
 ;;=^5003784
 ;;^UTILITY(U,$J,358.3,34210,0)
 ;;=G24.09^^134^1731^16
 ;;^UTILITY(U,$J,358.3,34210,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34210,1,3,0)
 ;;=3^Tardive Dystonia
 ;;^UTILITY(U,$J,358.3,34210,1,4,0)
 ;;=4^G24.09
 ;;^UTILITY(U,$J,358.3,34210,2)
 ;;=^5003786
 ;;^UTILITY(U,$J,358.3,34211,0)
 ;;=G25.1^^134^1731^11
 ;;^UTILITY(U,$J,358.3,34211,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34211,1,3,0)
 ;;=3^Medication-Induced Postural Tremor
 ;;^UTILITY(U,$J,358.3,34211,1,4,0)
 ;;=4^G25.1
 ;;^UTILITY(U,$J,358.3,34211,2)
 ;;=^5003792
 ;;^UTILITY(U,$J,358.3,34212,0)
 ;;=G25.71^^134^1731^14
 ;;^UTILITY(U,$J,358.3,34212,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34212,1,3,0)
 ;;=3^Tardive Akathisia
 ;;^UTILITY(U,$J,358.3,34212,1,4,0)
 ;;=4^G25.71
 ;;^UTILITY(U,$J,358.3,34212,2)
 ;;=^5003799
 ;;^UTILITY(U,$J,358.3,34213,0)
 ;;=G25.79^^134^1731^9
 ;;^UTILITY(U,$J,358.3,34213,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34213,1,3,0)
 ;;=3^Medication-Induced Movement Disorder,Other
 ;;^UTILITY(U,$J,358.3,34213,1,4,0)
 ;;=4^G25.79
 ;;^UTILITY(U,$J,358.3,34213,2)
 ;;=^5003800
 ;;^UTILITY(U,$J,358.3,34214,0)
 ;;=T43.205A^^134^1731^4
 ;;^UTILITY(U,$J,358.3,34214,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34214,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Init Encntr
 ;;^UTILITY(U,$J,358.3,34214,1,4,0)
 ;;=4^T43.205A
 ;;^UTILITY(U,$J,358.3,34214,2)
 ;;=^5050540
 ;;^UTILITY(U,$J,358.3,34215,0)
 ;;=T43.205D^^134^1731^5
 ;;^UTILITY(U,$J,358.3,34215,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34215,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Subseq Encntr
 ;;^UTILITY(U,$J,358.3,34215,1,4,0)
 ;;=4^T43.205D
 ;;^UTILITY(U,$J,358.3,34215,2)
 ;;=^5050541
 ;;^UTILITY(U,$J,358.3,34216,0)
 ;;=T43.205S^^134^1731^6
 ;;^UTILITY(U,$J,358.3,34216,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34216,1,3,0)
 ;;=3^Antidepressant Discontinuation Syndrome,Sequela
 ;;^UTILITY(U,$J,358.3,34216,1,4,0)
 ;;=4^T43.205S
 ;;^UTILITY(U,$J,358.3,34216,2)
 ;;=^5050542
 ;;^UTILITY(U,$J,358.3,34217,0)
 ;;=G25.71^^134^1731^7
 ;;^UTILITY(U,$J,358.3,34217,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34217,1,3,0)
 ;;=3^Medication-Induced Acute Akathisia
 ;;^UTILITY(U,$J,358.3,34217,1,4,0)
 ;;=4^G25.71
 ;;^UTILITY(U,$J,358.3,34217,2)
 ;;=^5003799
 ;;^UTILITY(U,$J,358.3,34218,0)
 ;;=G24.02^^134^1731^8
 ;;^UTILITY(U,$J,358.3,34218,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34218,1,3,0)
 ;;=3^Medication-Induced Acute Dystonia
 ;;^UTILITY(U,$J,358.3,34218,1,4,0)
 ;;=4^G24.02
 ;;^UTILITY(U,$J,358.3,34218,2)
 ;;=^5003785
 ;;^UTILITY(U,$J,358.3,34219,0)
 ;;=G21.0^^134^1731^12
 ;;^UTILITY(U,$J,358.3,34219,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34219,1,3,0)
 ;;=3^Neuroleptic Malignant Syndrome
 ;;^UTILITY(U,$J,358.3,34219,1,4,0)
 ;;=4^G21.0
 ;;^UTILITY(U,$J,358.3,34219,2)
 ;;=^5003771
 ;;^UTILITY(U,$J,358.3,34220,0)
 ;;=T50.905A^^134^1731^1
 ;;^UTILITY(U,$J,358.3,34220,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,34220,1,3,0)
 ;;=3^Adverse Effect of Medication,Other,Init Encntr
